Asset Details
Do you wish to reserve the book?
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Do you wish to request the book?
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
2019
Overview
The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- and poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.
Publisher
BMJ Publishing Group Ltd,BioMed Central,BioMed Central Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
/ Antineoplastic Agents, Immunological - administration & dosage
/ Antineoplastic Agents, Immunological - adverse effects
/ Antineoplastic Agents, Immunological - therapeutic use
/ Avelumab
/ Axitinib
/ Cancer
/ Carcinoma, Renal Cell - drug therapy
/ Carcinoma, Renal Cell - etiology
/ Carcinoma, Renal Cell - pathology
/ Death
/ Guidelines and Consensus Statements
/ Humans
/ Immune checkpoint inhibitor (ICI)
/ Immune checkpoint inhibitors
/ Kidney Neoplasms - drug therapy
/ Kidney Neoplasms - pathology
/ Medicine
/ Oncology
/ Patients
/ Phenols (Class of compounds)
/ Position Article and Guidelines
/ Practice Guidelines as Topic
/ Tyrosine
